Efficacy of Icotinib for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified

Efficacy of Icotinib for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified

Background and objective As the first epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in China, icotinib shows promising anticancer activity in vitro and vivo. The phase III clinical study (ICOGEN) showed that icotinib has a good efficacy and tolerability in Chinese patients wi...

Full description

Bibliographic Details
Main Authors: Yiping ZHANG, Beibei ZHANG, Chunxiao HE, Baochai LIN, Lan SHAO, Jufen CAI, Xinmin YU, Zhengbo SONG
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2013-03-01
Series:Chinese Journal of Lung Cancer
Subjects:
Lung neoplasms
Icotinib
EGFR mutation
Efficacy
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2013.03.04

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2013.03.04

Similar Items